



(51) International Patent Classification:

C07D 339/04 (2006.01) *A61P 1/16* (2006.01)
A61K 31/385 (2006.01)

(21) International Application Number:

PCT/IB2011/001550

(22) International Filing Date:

3 June 2011 (03.06.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/352,438 8 June 2010 (08.06.2010) US

(72) Inventor; and

(71) Applicant : **KANDULA, Mahesh** [IN/IN]; D. No. 11-61, G. Medapadu, Andhra Pradesh 533434 (IN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,


HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: CYSTEAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NASH



(57) Abstract: The disclosure herein provides a compound of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof. The steps of synthesis of compound of formula I is described. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, transdermal administration, or injection. Such compositions may be used to treatment of metabolic condition or neurodegenerative disorders or its associated complications.